Randomized forced titration to different doses of Technosphere ® insulin demonstrates reduction in postprandial glucose excursions and hemoglobin A1C in patients with type 2 diabetes

Journal of Diabetes Science and Technology

Volumn 2, Issue 1, 2008, Pages 47-57

  Tack, Cees J ^a   Christov, Vladimir ^b   De Galan, Bastiaan E ^a,c   Derwahl, Karl Michael ^d   Klausmann, Gerhard ^e   Pelikánová, Terezie ^f   Perušičová, Jindra ^g   Boss, Anders H ^h   Amin, Nikhil ^h   Kramer, David ^h   Petrucci, Richard ^h   Yu, Wen ^h  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d HUMBOLDT UNIVERSITY   (Germany)

^e Diabetes Center Aschaffenburg   (Germany)

^f INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^g CHARLES UNIVERSITY   (Czech Republic)

^h MannKind Corporation   (United States)

Author keywords

Diabetes; HbA1c; Inhaled insulin; Postprandial glucose; Technosphere insulin

Indexed keywords

EID: 68949134419     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229680800200108     Document Type: Article

References (27)

1. Saaddine JB, Cadwell B, Gregg EW, Engelgau MM, Vinicor F, Imperatore G, Narayan KM. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med. 2006;144:465-74.
2. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA (1c). Diabetes Care. 2003;26:881-5.
3. Qiao Q, Pyörälä K, Pyörälä M, Nissinen A, Lindström J, Tilvis R, Tuomilehto J. Two-hour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose. Eur Heart J. 2002;23:1267-75.
4. Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K, Hanefeld M. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care. 2000;23:1830-4.
5. Ceriello A. The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications. Diabetologia. 2003;46(Suppl 1):M9-16.
6. Ceriello A, Hanefeld M, Leiter L, Monnier L, Moses A, Owens D, Tajima N, Tuomilehto J. Postprandial glucose regulation and diabetic complications. Arch Intern Med. 2004;164:2090-5.
7. Home P. Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes. Curr Med Res Opin. 2005;21:989-98.
8. De Vegt F, Dekker JM, Ruhé HG, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ. Hyperglycaemia is associated with allcause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia. 1999;42:926-31.
9. Meigs JB, Nathan DM, D'Agostino RB Sr, Wilson PW. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care. 2002;25:1845-50.
10. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia. 1996;39:1577-83.
11. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95, 783 individuals followed for 12.4 years. Diabetes Care. 1999;22:233-40.
12. Bruce DG, Chisholm DJ, Storlien LH, Kraegen EW. Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes. Diabetes. 1988;37:736-44.
13. Luzio SD, Owens DR, Vora J, Dolben J, Smith H. Intravenous insulin simulates early insulin peak and reduces post-prandial hyperglycaemia/ hyperinsulinaemia in type 2 (non-insulindependent) diabetes mellitus. Diabetes Res. 1991;16:63-7.
14. Calles-Escandon J, Robbins DC. Loss of early phase of insulin release in humans impairs glucose tolerance and blunts thermic effect of glucose. Diabetes. 1987;36:1167-72.
15. Hirsch IB. Insulin analogues. N Engl J Med. 2005;352:174-83.
16. ®/insulin: mimicking endogenous insulin release. In: Rathbone M, Hadgraft J, Roberts M, Lane M, editors. Modified release drug delivery systems. 2nd ed. New York: Informa Healthcare USA, Inc.; 2007.
17. Steiner S, Pfützner A, Wilson BR, Harzer O, Heinemann L, Rave K. Technosphere/Insulin-proof of concept study with a new insulin formulation for pulmonary delivery. Exp Clin Endocrinol Diabetes. 2002;110:17-21.
18. Pfützner A, Mann AE, Steiner SS. Technosphere/Insulin- A new approach for effective delivery of human insulin via the pulmonary route. Diabetes Technol Ther. 2002;4:589-94.
19. Rave K, Heise T, Pfützner A, Boss AH. Coverage of postprandial blood glucose excursions with inhaled Technosphere Insulin in comparison to subcutaneously injected regular human insulin in subjects with type 2 diabetes. Diabetes Care. 2007;30:2307-8.
20. Boss AH, Rave K, Cheatham WW, Heise T. Inhaled Technosphere/Insulin: glucose elimination at the right time? Diabetes 2005;54(Suppl 1):A109.
21. Boss AH, Evans SH, Ren H, Harris R, Firsov I, Richardson P. Superior post prandial glucose control in patients with type 1 diabetes when using prandial Technosphere Insulin compared to NovoLog. Diabetologia. 2006;49:114-5.
22. Freemantle N, Blonde L, Duhot D, Hompesch M, Eggertsen R, Hobbs FD, Martinez L, Ross S, Bolinder B, Stridde E. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care. 2005;28:427-8.
23. Hunt LM, Valenzuela MA, Pugh JA. NIDDM patients' fears and hopes about insulin therapy. The basis of patient reluctance. Diabetes Care. 1997;20:292-8.
24. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord. 2002;26(Suppl 3):S18-24.
25. Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, Landgraf R, Kleinebreil L; The International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28:2673-9.
26. Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005;28:2543-5.
27. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U. S. population. Am J Respir Crit Care Med. 1999;159:179-87.